Providence physicians and scientists have been leading the way in melanoma research and treatment for more than 20 years. Our findings have resulted in new ways to boost immune response, which has improved the standard of care for patients with this aggressive malignancy.
The National Institutes of Health has awarded two significant grants to Providence Cancer Center researchers
An unprecedented international collaboration promises to take cancer treatment research to a new level and allow substantially more patients at Providence Cancer Center to take part in clinical trials every year.
Robert W. Franz, a supporter of cancer research at Providence and philanthropic leader here for more than 30 years, passed away Aug. 9 at Providence Portland Medical Center.
The Providence Thoracic Oncology Program emphasizes a multidisciplinary approach to cancer management. Our clinical trials program offers a broad array of innovative clinical research, including studies of new surgical techniques, radiation, chemotherapy, targeted therapy and immunotherapy agents, and tissue banking.
More than 150 people took part as Providence Cancer Center participated in Vice President Biden’s Cancer Moonshot Summit. The goal is to make a decade worth of advances toward a cure in five years, from increasing access to treatment and improving care to freeing trapped data and unleashing new breakthroughs.
We mourn the passing of Earle M. Chiles, 83, a long-time champion and supporter of providing exceptional health care for Providence patients in Oregon.
Excited by the promise and power of immunotherapy research, Providence Cancer Center supporters raised nearly $1 million in the month of May, with most of that coming at the 2016 Creating Hope through Innovation Dinner May 25.
Just a year into her career as a Providence Cancer Center radiation oncologist and scientist, Kristina Young, M.D., Ph.D., has been recognized as...
Providence researchers have identified an immunotherapy approach that synergizes with radiation so well it not only eliminated the tumor in most preclinical models with pancreatic cancer, it found and destroyed distant, cancer cells – which could have grown into lethal metastatic tumors.